A significant body of medical inquiry and parental concern has long centered on a widely administered antiviral medication for influenza in children, grappling with the question of whether the drug itself or the underlying viral infection was the root cause of serious neurological and psychological disturbances. For years, reports of seizures, disorientation, and vivid hallucinations in young patients prescribed this treatment fueled considerable apprehension among healthcare professionals and the families entrusting their children’s care to them, creating an atmosphere of uncertainty surrounding the medication’s safety profile.
However, groundbreaking new research emerging from the Monroe Carell Jr. Children’s Hospital at Vanderbilt is poised to fundamentally alter this long-standing perception of oseltamivir, a medication more commonly recognized by its brand name, Tamiflu. The study, meticulously conducted and recently published in the esteemed journal JAMA Neurology, presents compelling evidence that challenges the previous concerns, suggesting that children who received oseltamivir during an influenza episode were, in fact, less susceptible to experiencing these severe neuropsychiatric events, which encompass conditions such as seizures, altered states of consciousness, and hallucinatory experiences.
This pivotal research overturns the prevailing notion, indicating that the influenza virus itself, rather than the prescribed antiviral treatment, is the primary antecedent to these neurological and psychiatric complications. The lead investigator, Dr. James Antoon, an assistant professor of Pediatrics in the Division of Pediatric Hospital Medicine at Monroe Carell, articulated the study’s core revelation: "Our findings demonstrated what many pediatricians have long suspected, that the flu, not the flu treatment, is associated with neuropsychiatric events." He further elaborated, suggesting a paradoxical protective effect: "In fact, oseltamivir treatment seems to prevent neuropsychiatric events rather than cause them."
The researchers meticulously identified three critical findings that, when considered collectively, strongly implicate the influenza infection as the principal instigator of these adverse outcomes. Their analysis revealed that the influenza infection itself was demonstrably linked to a higher incidence of neuropsychiatric events when compared to children who did not contract the flu, irrespective of whether they had been treated with oseltamivir. Crucially, within the cohort of children diagnosed with influenza, those who underwent treatment with oseltamivir exhibited a substantial reduction, approximately 50%, in the occurrence of neuropsychiatric events. Furthermore, the study observed that children who did not have influenza but received oseltamivir as a prophylactic measure displayed an incidence rate of these events comparable to that of children who had no exposure to the influenza virus. Dr. Antoon synthesized these findings, stating, "Taken together, these three findings do not support the theory that oseltamivir increases the risk of neuropsychiatric events. It’s the influenza."
This comprehensive investigation was built upon a robust, large-scale analysis of de-identified health records pertaining to children and adolescents aged 5 to 17 years. The data originated from individuals enrolled in Tennessee Medicaid, spanning a four-year period from July 1, 2016, to June 30, 2020. The study’s extensive scope involved tracking a cohort of 692,295 children, with a median age of 11 years. During this extensive observation period, a total of 1,230 serious neuropsychiatric events were meticulously documented, subdivided into 898 neurologic events and 332 psychiatric events. The spectrum of documented clinical outcomes was broad, encompassing neurological conditions such as seizures, encephalitis (inflammation of the brain), altered mental status, ataxia (coordination disorders) and other movement abnormalities, visual disturbances, dizziness, headaches, and sleep disorders. On the psychiatric front, the recorded outcomes included behaviors indicative of suicidal ideation or self-harm, mood disorders, and instances of psychosis or hallucinations.
The implications of these findings are profound, particularly for families navigating the complexities of childhood illness and treatment decisions. Dr. Antoon highlighted the timeliness of this research, noting, "The 2024-2025 influenza season highlighted the severity of influenza-associated neurologic complications, with many centers reporting increased frequency and severity of neurologic events during the most recent season." He underscored the importance of accurate risk-benefit communication: "It is important for patients and families to know the true risk-benefit profile of flu treatments, such as oseltamivir, that are recommended by the American Academy of Pediatrics."
Echoing this sentiment, senior author Dr. Carlos Grijalva, a professor of Health Policy and Biomedical Informatics at Vanderbilt University Medical Center, emphasized the enduring critical role of early intervention in managing influenza. He stated, "These flu treatments are safe and effective, especially when used early in the course of clinical disease." The research team expressed their hope that the study’s outcomes will serve to alleviate the anxieties of both caregivers and healthcare providers, fostering greater confidence in the safety and efficacy of oseltamivir and its crucial role in mitigating the severity of flu-related complications in pediatric populations. This research was generously supported by grants from the National Institutes of Health, specifically grants K23AI168496, K24AI148459, and P50HD106446.
About the Author
